Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The United States Patent Office has issued a patent covering Nuvo Research's compositions and methods of using Pennsaid (diclofenac sodium topical solution) 2.0% w/w (Pennsaid 2% Patent), which will expire on 21 April 2028.
Subscribe to our email newsletter
Pennsaid is a topical non-steroidal anti-inflammatory drug (NSAID). Pennsaid 2%, which is not approved by the FDA, contains 2% diclofenac sodium compared to 1.5% for original Pennsaid.
If the FDA approves, Pennsaid 2% will be indicated for the treatment of the signs and symptoms of osteoarthritis of the knee.
Nuvo vice president and general counsel Tina Loucaides said, "This patent, together with our recently announced method of use patent for PENNSAID and PENNSAID 2% gives us a strong patent portfolio that will support the PENNSAID franchise."
Mallinckrodt, the pharmaceuticals business of Covidien and Nuvo’s US licensing partner, advised the FDA acceptance of a new drug application for Pennsaid (diclofenac sodium topical solution) 2.0% w/w for review.